Sugi Predict

Sugi Predict / Compounds / SCHEMBL23849403

SCHEMBL23849403

SCHEMBL23849403

C=CCCC(CCCCCCC)OC(=O)N[C@@H](CC(C)C)C(=O)OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BIRC2 Q13490 2/20 0.47
▸ CTSK P43235 2/20 0.44
▸ TAS1R3 Q7RTX0 1/20 0.40
▸ TAS1R1 Q7RTX1 1/20 0.40
▸ PLA2G2C Q5R387 1/20 0.40
▸ ABCB1 P08183 1/20 0.39
▸ DAGLA Q9Y4D2 3/20 0.39
▸ DAGLB Q8NCG7 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ NR1I2 O75469 1/20 0.39
▸ ABHD16A O95870 1/20 0.39
▸ LPL P06858 1/20 0.39
▸ LIPC P11150 1/20 0.39
▸ PNLIP P16233 1/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ FASN P49327 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ PLA2G7 Q13093 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23849263 0.95 BIRC2 (0.47) BIRC2CTSKTAS1R3TAS1R1ABCB1
SCHEMBL23849171 0.92 CTSK (0.44) BIRC2CTSKPLA2G2CDAGLADAGLB
SCHEMBL23833896 0.90 PLA2G2A (0.47) CTSKPLA2G2CDAGLADAGLB
SCHEMBL23833899 0.90 PLA2G2A (0.47) CTSKPLA2G2CDAGLADAGLB
SCHEMBL23833974 0.85 PLA2G2A (0.47) CTSKPLA2G2C
SCHEMBL23833972 0.85 PLA2G2A (0.47) CTSKPLA2G2C
SCHEMBL25508399 0.81 BIRC2 (0.38) BIRC2CTSKDAGLADAGLBMAPT
SCHEMBL23849262 0.79 BIRC2 (0.36) BIRC2CTSKDAGLADAGLBMAPT
SCHEMBL25508614 0.79 BIRC2 (0.64) BIRC2TAS1R3TAS1R1
SCHEMBL23833874 0.78 PLA2G2A (0.39) BIRC2CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 — — US disclosed
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 — — US disclosed
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA, INC. 2023-05-18 — — US disclosed
WO-2021188620-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION COCRYSTAL PHARMA INC. (US) 2021-09-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151034-A1 PEPTIDOMIMETIC N5-METHYL-N2-(NONANOYL-L-LEUCYL)-L-GLUTAMINATE DERIVATIVES, TRIAZASPIRO[4.14]NONADECANE DERIVATIVES AND SIMILAR COMPOUNDS AS INHIBITORS OF NOROVIRUS AND CORONAVIRUS REPLICATION ASNS, GLUL, GNMT BIRC2 3019/4885CTSK 1842/4885TAS1R3 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.